Edwards Lifesciences

Trial Studied Severe, Symptomatic Aortic Stenosis Patients at Intermediate Risk for Surgery CHICAGO, April 3, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement […]

CHICAGO, April 2, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully achieved its primary endpoint at two years. The results of the study […]

IRVINE, Calif., March 16, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic […]

IRVINE, Calif., March 2, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration approval to expand use of the Edwards SAPIEN XT transcatheter heart valve for pulmonic valve replacement procedures. The approval enables the treatment of […]

IRVINE, Calif., Jan. 15, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration approval for an expanded indication study of its most advanced transcatheter aortic heart valve, the Edwards SAPIEN 3 valve. The investigational device exemption […]